Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097096 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
A Phase 2 study of Alzheimers Disease, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
- 20
- Study locations
NCT01097096 is a Phase 2 study of Alzheimers Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 177 participants, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT01097096, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CAD106
- BIOLOGICAL Alum
- BIOLOGICAL MF59
Study Locations (20)
Other
- Novartis Investigative Site - Antwerp
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Magdeburg
- Novartis Investigative Site - Nuremberg
- Novartis Investigative Site - Amsterdam
Ontario
- Novartis Investigative Site - Toronto
- Novartis Investigative Site - Toronto
Quebec
- Novartis Investigative Site - Greenfield Park
- Novartis Investigative Site - Montreal
RM
- Novartis Investigative Site - Roma
- Novartis Investigative Site - Roma
California
- Novartis Investigative Site - Costa Mesa
Colorado
- Novartis Investigative Site - Boulder
Florida
- Novartis Investigative Site - Hollywood
Indiana
- Novartis Investigative Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01097096
The ClinicalTrials.gov registry entry for NCT01097096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (96% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01097096 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Ontario, Quebec.
Frequently Asked Questions
What is clinical trial NCT01097096 about?
NCT01097096 is a clinical study titled "Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients". This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
What is the current status of trial NCT01097096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2010-03. Estimated completion is 2012-12.
What conditions does trial NCT01097096 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01097096?
The interventions under investigation include: Placebo (BIOLOGICAL), CAD106 (BIOLOGICAL), Alum (BIOLOGICAL), MF59 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01097096?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01097096 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.